Fecundis
Fecundis is a Barcelona-based biotech developing HyperSperm, a sperm capacitation kit for IVF/ICSI, and a pipeline (HyperSperm-IUI, HyperFlow microfluidics, Spermy AI) sold B2B to fertility clinics across Europe and Latin America.
- Company typePrivate
- Founded2019
- HeadquartersBuenos Aires, Argentina
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fecundis does
Fecundis is a biotechnology company developing sperm-centered technologies for assisted reproduction, with a focus on recreating physiological sperm capacitation in vitro to improve IVF and ICSI outcomes. Its lead product, HyperSperm, is a sequential-step laboratory kit that brings biochemical and physical cues associated with natural capacitation into standard sperm preparation workflows, without requiring changes to embryologist technique. The product is supported by peer-reviewed clinical evidence, including multicenter prospective sibling oocyte studies showing improved blastocyst development rates (55.6% vs 47.9%, p=0.0038) and higher usable blastocyst rates in donor oocytes (67.9% vs 43.8%, p=0.0122), alongside in vitro data on 135 human semen samples confirming no compromise to sperm viability, DNA integrity, or acrosomal structure.
The company's pipeline extends the core capacitation science into adjacent formats and modalities: HyperSperm-IUI adapts the approach to intrauterine insemination; HyperFlow, developed with Beonchip S.L. under the EU Eurostars Programme, automates HyperSperm using microfluidics; and Spermy is an AI-assisted predictive tool for ART outcomes currently in exploratory development. Fecundis operates a B2B go-to-market, selling consumable kits directly to fertility clinics and IVF laboratories in Europe (headquartered at Barcelona Science Park) and Latin America (offices in Buenos Aires and Rosario), using peer-reviewed publications and clinical evidence as its primary marketing channel. Revenue mechanics are kit-based and quote-priced rather than publicly disclosed, and the company is backed by investors including Capital Cell, Dune Glass Capital, Grid Exponential, and Zentynel, having closed a ~$2.63M round in October 2024 following a $100K seed in 2019.
Fecundis firmographics
Firmographics- Name
- Fecundis
- Legal name
- FECUNDIS LAB S.L.
- Website
- https://fecundis.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Fecundis is a Barcelona-based biotech developing HyperSperm, a sperm capacitation kit for IVF/ICSI, and a pipeline (HyperSperm-IUI, HyperFlow microfluidics, Spermy AI) sold B2B to fertility clinics across Europe and Latin America.
- Ownership category
- akta.pro rank
Fecundis industry classification
Industry- Product category
- Assisted Reproductive Technology Products
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Livestock & Poultry Nutrition (Feed & Premixes) (HLAMAHAD)
Keywords
Where Fecundis is headquartered
LocationHeadquarters
- HQ city
- Buenos Aires
- HQ country
- Argentina
- HQ region
- Latin America
Offices3 records
Markets served
Fecundis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- HyperSperm Kit Sales: Fecundis generates revenue through the sale of its HyperSperm sperm capacitation kits to fertility clinics and IVF laboratories. The product is a consumable laboratory reagent kit that is integrated into standard IVF laboratory workflows.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Fecundis product offering
Product offeringCore offering
Fecundis develops and sells sperm capacitation technologies for use in assisted reproduction. Its lead product, HyperSperm, is a sequential-step laboratory kit that recreates key biochemical signals of physiological sperm capacitation in vitro, integrating into standard IVF and ICSI laboratory workflows. The portfolio also includes the in-development HyperSperm-IUI adaptation, the microfluidic automation device HyperFlow, and the AI-assisted prediction tool Spermy.
Product overview
Fecundis is a biotechnology company developing sperm-centered technologies for assisted reproduction. The core product is HyperSperm, a sequential-step laboratory kit that recreates physiological sperm capacitation in vitro for IVF and ICSI procedures. The product portfolio includes HyperSperm-IUI (adaptation for intrauterine insemination), HyperFlow (microfluidics-based automation of HyperSperm), and Spermy (AI-assisted outcome prediction tool in development). The offerings work together as a comprehensive suite addressing different stages and methods of sperm preparation in assisted reproduction.
Differentiator
Problem solved
Functional benefit
Brands
- HyperSperm: Lead product - a sequential-step kit designed to recreate in vitro key physiological transitions associated with sperm capacitation under controlled laboratory conditions for IVF and ICSI.
- HyperSperm - IUI
- HyperFlow
- Spermy
Products and services
- HyperSperm A sequential-step laboratory kit designed to recreate in vitro key physiological transitions associated with sperm capacitation under controlled conditions. It supports a more biologically informed sperm preparation process for IVF and ICSI by bringing relevant biochemical and physical cues into the laboratory workflow, for use by fertility clinics and IVF laboratories.
- HyperSperm - IUI An adaptation of the HyperSperm biological approach specifically for intrauterine insemination (IUI) procedures, intended for fertility clinics performing IUI. Currently in development.
- HyperFlow A fully automated microfluidic device designed to select and functionally enhance sperm, automating the HyperSperm approach for improved success rates in assisted reproduction. Developed in collaboration with Beonchip and Fertilitets Klinikken Lygten.
- Spermy An AI-assisted prediction tool for outcomes in assisted reproduction that uses data-driven approaches to support prediction, insight, and decision-making in ART. Currently in exploratory/research phase.
Quantifiable outcome
- Blastocyst development rate increased to 55.6% vs 47.9% (p=0.0038) with HyperSperm treatment compared to standard preparation
- +3 more outcomes
Companies that use Fecundis
Customer profileSegments1 record
Ideal customer profiles1 record
Fecundis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Fecundis partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and major.
- BeonchipcoreSpanish biotech company collaborating on the development of HyperFlow, a microfluidic device for sperm selection and functional enhancement. Partner in the Eureka-Eurostars HyperFlow project.
- Fertilitets Klinikken LygtencoreDanish fertility clinic collaborating on the HyperFlow project for development and validation of the automated sperm selection device.
- FertyamajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- Copenhagen Fertility CentermajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- PregnamajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- Exseed HealthmajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- FerttymajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- GametiamajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- NatuvitromajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- InvitromajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- FertilabmajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- CIRH EuginmajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- EuginmajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- Quironsalud ZaragozamajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
- WeFIVmajorClinical partner providing support for development and clinical validation of Fecundis sperm capacitation technologies.
Recent moves6 records
Expansion highlights6 records
Fecundis competitors and assessment
Company assessmentDirect peers
- Vitrolife: Swedish global leader in ART media and consumables, including sperm preparation media and IVF/ICSI lab solutions. Directly comparable to Fecundis as a B2B supplier of consumables that improve IVF outcomes in clinical labs.
- Genea Biomedx: ART-focused medical device company (spun out of Genea Fertility) that develops lab instruments and consumables for IVF clinics. Comparable to Fecundis as a specialist vendor targeting IVF lab workflow improvements.
- Hamilton Thorne: Provider of precision instruments, consumables, and software for the ART and animal breeding markets, including sperm analysis and IVF lab tools. Comparable as a supplier of ART-specific consumables and devices used in clinical embryology workflows.
- Esco Medical: Manufacturer of ART/IVF equipment and consumables including time-lapse incubators and IVF workstations used in fertility clinics. Comparable to Fecundis as a specialist vendor of products designed to improve IVF lab outcomes and workflow.
- Rocket Medical: UK-based medical device company producing ART/IVF consumables and devices (e.g., embryo transfer catheters, gamete handling products). Comparable to Fecundis as a specialty vendor of consumables used in IVF procedures.
Broad incumbents
- CooperSurgical: Large diversified women's health and ART consumables/medical device company (parent CooperCompanies) with Wallace, ORIGIO, and Genesis Genetics brands. Comparable as a broad incumbent selling ART lab consumables and devices to fertility clinics worldwide.
- FUJIFILM Irvine Scientific: Major cell culture media manufacturer (now part of FUJIFILM) supplying media for ART/IVF and cell therapy applications. Directly relevant as a large-scale supplier of consumables used in IVF laboratories, including sperm prep and embryo culture media.
- Merck KGaA (Sigma-Aldrich Life Science): Global life science tools and consumables provider (parent of Sigma-Aldrich/Merck Millipore) supplying cell culture media and reagents used in ART labs. Comparable as a broad incumbent offering consumables and reagents to IVF laboratories worldwide.
- Ferring Pharmaceuticals: Global specialty biopharmaceutical company focused on reproductive medicine and women's health (including fertility treatments like Menopur). Comparable as a broader incumbent serving the IVF value chain via drugs and adjunctive therapies, relevant for distribution or partnership.
Emerging players
- Future Fertility: Early-stage company applying AI and computer vision to evaluate egg and sperm quality for IVF clinics. Comparable to Fecundis as an emerging ART technology company targeting clinical decision-making and outcome improvement in fertility labs, complementing Spermy's AI roadmap.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Fecundis social profiles
Digital presenceFecundis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fecundis leadership team
Management profileNumber of profiles
Profiles4 records
Fecundis funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fecundis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fecundis
What does Fecundis do?
Fecundis develops and sells sperm capacitation technologies for use in assisted reproduction. Its lead product, HyperSperm, is a sequential-step laboratory kit that recreates key biochemical signals of physiological sperm capacitation in vitro, integrating into standard IVF and ICSI laboratory workflows. The portfolio also includes the in-development HyperSperm-IUI adaptation, the microfluidic automation device HyperFlow, and the AI-assisted prediction tool Spermy.
Is Fecundis a public or private company?
Fecundis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Fecundis founded?
Fecundis was founded in 2019. It employs 11 to 50 people.
Where is Fecundis based?
Fecundis is headquartered in Buenos Aires, Argentina, in the Latin America region.
How does Fecundis make money?
One revenue line is on record: hyperSperm Kit Sales.
Who are Fecundis's main competitors?
Direct peers on record are Vitrolife, Genea Biomedx, Hamilton Thorne, Esco Medical and Rocket Medical. Broad incumbents are CooperSurgical, FUJIFILM Irvine Scientific, Merck KGaA (Sigma-Aldrich Life Science) and Ferring Pharmaceuticals. Future Fertility is listed as an emerging player.
Does Fecundis have an API?
No public API is recorded for Fecundis.
What industry is Fecundis in?
Fecundis's product category is Assisted Reproductive Technology Products. Its primary akta.pro industry code is HLAMAHAD, Livestock & Poultry Nutrition (Feed & Premixes). Its NAICS code is 334510 and its SIC code is 3845.